carnitine has been researched along with Diabetes Mellitus in 70 studies
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Sitagliptin and clonidine are effective curing drugs for controlling diabetes and hypertension, while insulin and norepinephrine are the biomarkers of these two diseases." | 8.12 | Chiral Luminescent Sensor Eu-BTB@d-Carnitine Applied in the Highly Effective Ratiometric Sensing of Curing Drugs and Biomarkers for Diabetes and Hypertension. ( Ding, B; Huo, J; Jiang, YP; Liu, YY; Shi, YF; Sun, PP; Wang, K; Wang, XR; Wang, XZ; Zhang, ZQ; Zhu, NJ, 2022) |
| " To investigate associations between acyl-carnitines and cardiovascular function as indexed by imaging measurements." | 8.02 | Exacerbation of cardiovascular ageing by diabetes mellitus and its associations with acyl-carnitines. ( Chew, H; Ching, J; Chow, VJ; Ewe, SH; Gao, F; Keng, BM; Koh, AS; Koh, WP; Kovalik, JP; Lee, LS; Leng, S; Tan, HC; Tan, RS; Tan, TY; Teo, LL; Zhao, X; Zhong, L, 2021) |
| "The important pathological consequences of insulin resistance arise from the detrimental effects of accumulated long-chain fatty acids and their respective acylcarnitines." | 7.83 | Decreased acylcarnitine content improves insulin sensitivity in experimental mice models of insulin resistance. ( Dambrova, M; Grinberga, S; Kuka, J; Liepinsh, E; Makarova, E; Makrecka-Kuka, M; Sevostjanovs, E; Svalbe, B; Volska, K, 2016) |
| "L-Carnitine concentration was determined in vastus lateralis and abdominal rectus muscle tissue from 15 patients with diabetes mellitus and 66 controls." | 7.65 | Carnitine concentration in skeletal muscle tissue from patients with diabetes mellitus. ( Cederblad, G; Lundholm, K; Scherstén, T, 1977) |
| "Nowadays, the treatment of diabetes mellitus is based on the variable use and combination of diet, antidiabetic oral agents (metformin, sulphanylureas, glynides, acarbose and thiazolidinediones) and insulin or its analogs, depending on the type of diabetes and the needs of the patient." | 6.43 | Role of antioxidants, essential fatty acids, carnitine, vitamins, phytochemicals and trace elements in the treatment of diabetes mellitus and its chronic complications. ( Ghiyasaldin, S; Guastamacchia, E; Licchelli, B; Resta, F; Sabbà, C; Tafaro, E; Triggiani, V, 2006) |
| "Carnitine deficiency was defined as a free carnitine level of less than 40 micromol/L." | 5.34 | Association of carnitine deficiency in Indian continuous ambulatory peritoneal dialysis patients with anemia, erythropoietin use, residual renal function, and diabetes mellitus. ( Abraham, G; Ashok, BS; Baben, B; Jayanthi, V; Leslie, N; Ramalakshmi, S, 2007) |
| "We orally administered L-carnitine, which exerts protective effects on the mitochondria, to obesity-induced DN (db/db) mice for 8 weeks." | 4.12 | Effects of L-Carnitine Treatment on Kidney Mitochondria and Macrophages in Mice with Diabetic Nephropathy. ( Imakiire, T; Ishikiriyama, T; Ito, S; Kinoshita, M; Kumagai, H; Nakashima, H; Nakashima, M; Oshima, N; Seki, S; Yamagata, A, 2022) |
| " Sitagliptin and clonidine are effective curing drugs for controlling diabetes and hypertension, while insulin and norepinephrine are the biomarkers of these two diseases." | 4.12 | Chiral Luminescent Sensor Eu-BTB@d-Carnitine Applied in the Highly Effective Ratiometric Sensing of Curing Drugs and Biomarkers for Diabetes and Hypertension. ( Ding, B; Huo, J; Jiang, YP; Liu, YY; Shi, YF; Sun, PP; Wang, K; Wang, XR; Wang, XZ; Zhang, ZQ; Zhu, NJ, 2022) |
| "Our data suggest three possible clinically actionable endotypes in primary OA: muscle weakness, arginine deficit and low inflammatory OA." | 4.02 | Endotypes of primary osteoarthritis identified by plasma metabolomics analysis. ( Furey, A; Liu, M; Rahman, P; Randell, EW; Sun, G; Werdyani, S; Zhai, G; Zhang, H, 2021) |
| " To investigate associations between acyl-carnitines and cardiovascular function as indexed by imaging measurements." | 4.02 | Exacerbation of cardiovascular ageing by diabetes mellitus and its associations with acyl-carnitines. ( Chew, H; Ching, J; Chow, VJ; Ewe, SH; Gao, F; Keng, BM; Koh, AS; Koh, WP; Kovalik, JP; Lee, LS; Leng, S; Tan, HC; Tan, RS; Tan, TY; Teo, LL; Zhao, X; Zhong, L, 2021) |
| "The important pathological consequences of insulin resistance arise from the detrimental effects of accumulated long-chain fatty acids and their respective acylcarnitines." | 3.83 | Decreased acylcarnitine content improves insulin sensitivity in experimental mice models of insulin resistance. ( Dambrova, M; Grinberga, S; Kuka, J; Liepinsh, E; Makarova, E; Makrecka-Kuka, M; Sevostjanovs, E; Svalbe, B; Volska, K, 2016) |
| " Since the clinical utility of metformin in diabetes is probably traceable to inhibition of gluconeogenesis, its use as an adjunct to HCA/carnitine treatment of obesity in diabetics deserves evaluation, particularly as metformin therapy itself tends to reduce body weight." | 3.70 | Utility of metformin as an adjunct to hydroxycitrate/carnitine for reducing body fat in diabetics. ( McCarty, MF, 1998) |
| "To elucidate the relationship between carnitine metabolism and plasma ketone body concentrations in moderately obese patients with mild glucose intolerance, the ketone body and carnitine levels in the basal state were determined in 72 obese patients: 20 with normal glucose tolerance (NGT), 29 with impaired glucose tolerance (IGT), and 23 with non-insulin-dependent diabetes mellitus (NIDDM) having a fasting plasma glucose (FPG) level of less than 200 mg/dl." | 3.69 | Changes in carnitine metabolism with ketone body production in obese glucose-intolerant patients. ( Imamura, K; Inokuchi, T; Isogai, S; Nomoto, K; Nomura, K, 1995) |
| "L-Carnitine concentration was determined in vastus lateralis and abdominal rectus muscle tissue from 15 patients with diabetes mellitus and 66 controls." | 3.65 | Carnitine concentration in skeletal muscle tissue from patients with diabetes mellitus. ( Cederblad, G; Lundholm, K; Scherstén, T, 1977) |
| "L-carnitine is a very popular food supplement due to its safety profile, antioxidant-type activity and suggested effects on energy metabolism pathways." | 2.52 | Risks and benefits of carnitine supplementation in diabetes. ( Dambrova, M; Liepinsh, E, 2015) |
| "Nowadays, the treatment of diabetes mellitus is based on the variable use and combination of diet, antidiabetic oral agents (metformin, sulphanylureas, glynides, acarbose and thiazolidinediones) and insulin or its analogs, depending on the type of diabetes and the needs of the patient." | 2.43 | Role of antioxidants, essential fatty acids, carnitine, vitamins, phytochemicals and trace elements in the treatment of diabetes mellitus and its chronic complications. ( Ghiyasaldin, S; Guastamacchia, E; Licchelli, B; Resta, F; Sabbà, C; Tafaro, E; Triggiani, V, 2006) |
| "Carnitine is an ammo acid derivative found in high energy demanding tissues (skeletal muscles, myocardium, the liver and the suprarenal glands)." | 2.42 | Carnitine metabolism and deficit--when supplementation is necessary? ( Evangeliou, A; Vlassopoulos, D, 2003) |
| "glycogenosis type II and III), lysosomal storage diseases (e." | 2.41 | Metabolic cardiomyopathies. ( Guertl, B; Hoefler, G; Noehammer, C, 2000) |
| "L-carnitine treatment enhanced microvascular perfusion, reinforced endothelial barrier function, repressed the endothelial inflammatory response, and maintained the microvascular structure in db/db mice." | 1.91 | L-carnitine alleviates cardiac microvascular dysfunction in diabetic cardiomyopathy by enhancing PINK1-Parkin-dependent mitophagy through the CPT1a-PHB2-PARL pathways. ( Chen, A; Chen, J; Chen, Y; Chen, Z; Ge, J; Li, C; Li, Q; Li, S; Li, Y; Liu, M; Lu, D; Qian, J; Shen, L; Xia, Y; Xu, F; Yan, X; Yin, M; Zhou, Y, 2023) |
| "Fasting insulin sensitivity was measured using homeostatic model assessment 2 (HOMA2), and adipose tissue was measured using dual-energy x-ray absorptiometry (DEXA)." | 1.43 | Superior Glucose Tolerance and Metabolomic Profiles, Independent of Adiposity, in HIV-Infected Women Compared With Men on Antiretroviral Therapy. ( Culver, J; Jenkins, CA; Koethe, JR; Petucci, C; Shepherd, BE; Sterling, TR, 2016) |
| "Carnitine deficiency was defined as a free carnitine level of less than 40 micromol/L." | 1.34 | Association of carnitine deficiency in Indian continuous ambulatory peritoneal dialysis patients with anemia, erythropoietin use, residual renal function, and diabetes mellitus. ( Abraham, G; Ashok, BS; Baben, B; Jayanthi, V; Leslie, N; Ramalakshmi, S, 2007) |
| "Free carnitine excretion was reduced." | 1.28 | Differential excretion of xenobiotic acyl-esters of carnitine due to administration of pivampicillin and valproate. ( Bieber, LL; Jaszai, V; Kerner, J; Melegh, B, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (32.86) | 18.7374 |
| 1990's | 10 (14.29) | 18.2507 |
| 2000's | 12 (17.14) | 29.6817 |
| 2010's | 14 (20.00) | 24.3611 |
| 2020's | 11 (15.71) | 2.80 |
| Authors | Studies |
|---|---|
| Pereira, FWL | 1 |
| Paiva, SAR | 1 |
| Ito, S | 1 |
| Nakashima, M | 1 |
| Ishikiriyama, T | 1 |
| Nakashima, H | 1 |
| Yamagata, A | 1 |
| Imakiire, T | 1 |
| Kinoshita, M | 1 |
| Seki, S | 1 |
| Kumagai, H | 1 |
| Oshima, N | 1 |
| Hosseinkhani, S | 2 |
| Arjmand, B | 1 |
| Dilmaghani-Marand, A | 1 |
| Mohammadi Fateh, S | 1 |
| Dehghanbanadaki, H | 2 |
| Najjar, N | 2 |
| Alavi-Moghadam, S | 1 |
| Ghodssi-Ghassemabadi, R | 1 |
| Nasli-Esfahani, E | 1 |
| Farzadfar, F | 1 |
| Larijani, B | 1 |
| Razi, F | 2 |
| Salari, P | 1 |
| Bandarian, F | 1 |
| Asadi, M | 1 |
| Shirani, S | 1 |
| Pasalar, P | 1 |
| Shi, YF | 1 |
| Jiang, YP | 1 |
| Wang, XZ | 1 |
| Sun, PP | 1 |
| Zhu, NJ | 1 |
| Wang, K | 1 |
| Zhang, ZQ | 1 |
| Liu, YY | 1 |
| Huo, J | 1 |
| Wang, XR | 1 |
| Ding, B | 1 |
| Li, S | 1 |
| Liu, M | 2 |
| Chen, J | 1 |
| Chen, Y | 1 |
| Yin, M | 1 |
| Zhou, Y | 1 |
| Li, Q | 1 |
| Xu, F | 1 |
| Li, Y | 1 |
| Yan, X | 1 |
| Xia, Y | 1 |
| Chen, A | 1 |
| Lu, D | 1 |
| Li, C | 1 |
| Shen, L | 1 |
| Chen, Z | 1 |
| Qian, J | 1 |
| Ge, J | 1 |
| Davies, A | 1 |
| Wenzl, FA | 1 |
| Li, XS | 1 |
| Winzap, P | 1 |
| Obeid, S | 1 |
| Klingenberg, R | 1 |
| Mach, F | 1 |
| Räber, L | 1 |
| Muller, O | 1 |
| Matter, CM | 1 |
| Laaksonen, R | 1 |
| Wang, Z | 1 |
| Hazen, SL | 1 |
| Lüscher, TF | 1 |
| Molsberry, S | 1 |
| Bjornevik, K | 1 |
| Hughes, KC | 1 |
| Zhang, ZJ | 1 |
| Jeanfavre, S | 1 |
| Clish, C | 1 |
| Healy, B | 1 |
| Schwarzschild, M | 1 |
| Ascherio, A | 1 |
| Werdyani, S | 1 |
| Zhang, H | 1 |
| Sun, G | 1 |
| Furey, A | 1 |
| Randell, EW | 1 |
| Rahman, P | 1 |
| Zhai, G | 1 |
| Gadgil, MD | 1 |
| Kanaya, AM | 1 |
| Sands, C | 1 |
| Lewis, MR | 1 |
| Kandula, NR | 1 |
| Herrington, DM | 1 |
| Gao, F | 1 |
| Kovalik, JP | 1 |
| Zhao, X | 1 |
| Chow, VJ | 1 |
| Chew, H | 1 |
| Teo, LL | 1 |
| Tan, RS | 1 |
| Leng, S | 1 |
| Ewe, SH | 1 |
| Tan, HC | 1 |
| Tan, TY | 1 |
| Lee, LS | 1 |
| Ching, J | 1 |
| Keng, BM | 1 |
| Zhong, L | 1 |
| Koh, WP | 1 |
| Koh, AS | 1 |
| Carayol, M | 1 |
| Leitzmann, MF | 1 |
| Ferrari, P | 1 |
| Zamora-Ros, R | 1 |
| Achaintre, D | 1 |
| Stepien, M | 1 |
| Schmidt, JA | 1 |
| Travis, RC | 1 |
| Overvad, K | 1 |
| Tjønneland, A | 1 |
| Hansen, L | 1 |
| Kaaks, R | 1 |
| Kühn, T | 1 |
| Boeing, H | 1 |
| Bachlechner, U | 1 |
| Trichopoulou, A | 1 |
| Bamia, C | 1 |
| Palli, D | 1 |
| Agnoli, C | 1 |
| Tumino, R | 1 |
| Vineis, P | 1 |
| Panico, S | 1 |
| Quirós, JR | 1 |
| Sánchez-Cantalejo, E | 1 |
| Huerta, JM | 1 |
| Ardanaz, E | 1 |
| Arriola, L | 1 |
| Agudo, A | 1 |
| Nilsson, J | 1 |
| Melander, O | 1 |
| Bueno-de-Mesquita, B | 1 |
| Peeters, PH | 1 |
| Wareham, N | 1 |
| Khaw, KT | 1 |
| Jenab, M | 1 |
| Key, TJ | 1 |
| Scalbert, A | 1 |
| Rinaldi, S | 1 |
| Senyilmaz-Tiebe, D | 1 |
| Pfaff, DH | 1 |
| Virtue, S | 1 |
| Schwarz, KV | 1 |
| Fleming, T | 1 |
| Altamura, S | 1 |
| Muckenthaler, MU | 1 |
| Okun, JG | 1 |
| Vidal-Puig, A | 1 |
| Nawroth, P | 1 |
| Teleman, AA | 1 |
| Khan, HA | 1 |
| Alhomida, AS | 1 |
| Seiler, SE | 1 |
| Martin, OJ | 1 |
| Noland, RC | 1 |
| Slentz, DH | 1 |
| DeBalsi, KL | 1 |
| Ilkayeva, OR | 1 |
| An, J | 1 |
| Newgard, CB | 1 |
| Koves, TR | 1 |
| Muoio, DM | 1 |
| Dambrova, M | 3 |
| Liepinsh, E | 3 |
| Makrecka-Kuka, M | 1 |
| Makarova, E | 1 |
| Volska, K | 1 |
| Svalbe, B | 1 |
| Sevostjanovs, E | 1 |
| Grinberga, S | 2 |
| Kuka, J | 2 |
| Latkovskis, G | 1 |
| Strele, I | 1 |
| Konrade, I | 1 |
| Hartmane, D | 1 |
| Pugovics, O | 1 |
| Erglis, A | 1 |
| Koethe, JR | 1 |
| Jenkins, CA | 1 |
| Petucci, C | 1 |
| Culver, J | 1 |
| Shepherd, BE | 1 |
| Sterling, TR | 1 |
| Lopaschuk, GD | 2 |
| Hocher, B | 1 |
| Adamski, J | 1 |
| Koizumi, A | 1 |
| Golbidi, S | 1 |
| Ebadi, SA | 1 |
| Laher, I | 1 |
| Malaguarnera, M | 1 |
| Sirolli, V | 1 |
| Rossi, C | 1 |
| Di Castelnuovo, A | 1 |
| Felaco, P | 1 |
| Amoroso, L | 1 |
| Zucchelli, M | 1 |
| Ciavardelli, D | 1 |
| Di Ilio, C | 1 |
| Sacchetta, P | 1 |
| Bernardini, S | 1 |
| Arduini, A | 1 |
| Bonomini, M | 1 |
| Urbani, A | 1 |
| Walker, UA | 1 |
| Möder, M | 1 |
| Kiessling, A | 1 |
| Löster, H | 1 |
| Brüggemann, L | 1 |
| Evangeliou, A | 1 |
| Vlassopoulos, D | 1 |
| BEKAERT, J | 2 |
| DELTOUR, G | 2 |
| Steiber, AL | 1 |
| Weatherspoon, LJ | 1 |
| Spry, L | 1 |
| Davis, AT | 1 |
| Sweeney, M | 1 |
| Triggiani, V | 1 |
| Resta, F | 1 |
| Guastamacchia, E | 1 |
| Sabbà, C | 1 |
| Licchelli, B | 1 |
| Ghiyasaldin, S | 1 |
| Tafaro, E | 1 |
| Rufer, AC | 1 |
| Thoma, R | 1 |
| Benz, J | 1 |
| Stihle, M | 1 |
| Gsell, B | 1 |
| De Roo, E | 1 |
| Banner, DW | 1 |
| Mueller, F | 1 |
| Chomienne, O | 1 |
| Hennig, M | 1 |
| Rajasekar, P | 1 |
| Anuradha, CV | 1 |
| Ramalakshmi, S | 1 |
| Baben, B | 1 |
| Ashok, BS | 1 |
| Jayanthi, V | 1 |
| Leslie, N | 1 |
| Abraham, G | 1 |
| Celik, T | 1 |
| Kursaklioglu, H | 1 |
| Iyisoy, A | 1 |
| Jata, B | 1 |
| Altmaier, E | 1 |
| Ramsay, SL | 1 |
| Graber, A | 1 |
| Mewes, HW | 1 |
| Weinberger, KM | 1 |
| Suhre, K | 1 |
| Genuth, SM | 1 |
| Hoppel, CL | 1 |
| McCarty, MF | 3 |
| Rubin, EJ | 1 |
| Feuvray, D | 1 |
| Leblond, Y | 1 |
| Kachaner, J | 1 |
| Batisse, A | 1 |
| Fermont, L | 1 |
| Piechaud, JF | 1 |
| Ribierre, M | 1 |
| De Palo, E | 1 |
| Gatti, R | 1 |
| Sicolo, N | 1 |
| Padovan, D | 1 |
| Vettor, R | 1 |
| Federspil, G | 1 |
| Stearns, SB | 1 |
| Benzo, CA | 1 |
| Stevens, MJ | 1 |
| Feldman, EL | 1 |
| Greene, DA | 1 |
| Gamble, J | 1 |
| Morabito, E | 1 |
| Corsico, N | 1 |
| Marzo, A | 1 |
| Arrigoni Martelli, E | 1 |
| Inokuchi, T | 1 |
| Imamura, K | 1 |
| Nomura, K | 1 |
| Nomoto, K | 1 |
| Isogai, S | 1 |
| Yajnik, CS | 1 |
| Sardesai, BS | 1 |
| Bhat, DS | 1 |
| Naik, SS | 1 |
| Raut, KN | 1 |
| Shelgikar, KM | 1 |
| Orskov, H | 1 |
| Alberti, KG | 1 |
| Hockaday, TD | 1 |
| Kuratsune, H | 1 |
| Yamaguti, K | 1 |
| Lindh, G | 1 |
| Evengard, B | 1 |
| Takahashi, M | 1 |
| Machii, T | 1 |
| Matsumura, K | 1 |
| Takaishi, J | 1 |
| Kawata, S | 1 |
| Långström, B | 1 |
| Kanakura, Y | 1 |
| Kitani, T | 1 |
| Watanabe, Y | 1 |
| Guertl, B | 1 |
| Noehammer, C | 1 |
| Hoefler, G | 1 |
| Abdel Kader, MM | 1 |
| Zaki, AH | 1 |
| Tawadrous, GA | 1 |
| El-Hafez, MA | 1 |
| Abdou, MS | 1 |
| Dorgham, AH | 1 |
| Mitchell, ME | 1 |
| Sinclair-Smith, BC | 1 |
| Norlund, AE | 1 |
| Borrebaek, B | 1 |
| Cederblad, G | 1 |
| Lundholm, K | 1 |
| Scherstén, T | 1 |
| Dhalla, NS | 1 |
| Elimban, V | 1 |
| Rupp, H | 1 |
| Shihabi, ZK | 1 |
| Oles, KS | 1 |
| McCormick, CP | 1 |
| Penry, JK | 1 |
| Melegh, B | 1 |
| Kerner, J | 1 |
| Jaszai, V | 1 |
| Bieber, LL | 1 |
| Tahiliani, AG | 1 |
| McNeill, JH | 1 |
| Matsuyama, H | 1 |
| Morikawa, K | 1 |
| Hasegawa, T | 1 |
| Kuroda, M | 1 |
| Gross, MD | 1 |
| Harris, S | 1 |
| Beyer, RE | 1 |
| Böhmer, T | 1 |
| Rydning, A | 1 |
| Solberg, HE | 1 |
| Mackerer, CR | 1 |
| Mehlman, MA | 1 |
| Tobin, RB | 1 |
| Shipp, JC | 1 |
| Menahan, LA | 1 |
| Crass, MF | 1 |
| Chaudhuri, SN | 1 |
| Pettersen, JE | 1 |
| Bremer, J | 1 |
| Lowenstein, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Observational Cohort Study of Adipose Tissue and Immune Activation in Treated HIV Infection[NCT04439448] | 100 participants (Actual) | Observational | 2013-04-12 | Completed | |||
| Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease[NCT05719714] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2023-11-01 | Recruiting | ||
| In Vivo Study of Safety, Tolerability and Dosing Effect on SMN mRNA and Protein Levels of Valproic Acid in Patients With Spinal Muscular Atrophy[NCT00374075] | Phase 1 | 42 participants | Interventional | 2003-09-30 | Completed | ||
| Phase I/II Trial of Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy Type I (CARNI-VAL Type I)[NCT00661453] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Multi-center Phase II Trial of Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy (SMA CARNI-VAL Trial)[NCT00227266] | Phase 2 | 94 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00661453)
Timeframe: -2 weeks, time 0, 3 months, 6 months
| Intervention | g (Mean) | |||||
|---|---|---|---|---|---|---|
| Lean Mass Baseline | Lean Mass 3 months | Lean Mass 6 months | Fat Mass Baseline | Fat Mass 3 months | Fat Mass 6 months | |
| SMA Type 1 | 4317.15 | 4993.92 | 5133.83 | 3011.37 | 3618.25 | 4316.08 |
The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mV (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 2.28 | 2.32 |
| Cohort 1b Sitters Treatment | 2.93 | 2.37 |
| Cohort 2 Standers and Walkers - Treatment | 5.52 | 6.56 |
The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mV (Median) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 1.91 | 1.44 |
| Cohort 1b Sitters Treatment | 2.2 | 1.8 |
| Cohort 2 Standers and Walkers - Treatment | 5.3 | 5.85 |
The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mVms (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 5.46 | 5.28 |
| Cohort 1b Sitters Treatment | 5.45 | 5.26 |
| Cohort 2 Standers and Walkers - Treatment | 14.85 | 16.26 |
The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mVms (Median) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 3.6 | 3.74 |
| Cohort 1b Sitters Treatment | 4.6 | 3.4 |
| Cohort 2 Standers and Walkers - Treatment | 13.65 | 16.85 |
Comparison of Modified Hammersmith Change from baseline to 6 months. Scores range from 0 to 40. A higher score indicates a better outcome. This scale is used to assess gross motor abilities of non-ambulant children with SMA in multiple research trials as well as in clinical settings. (NCT00227266)
Timeframe: 0 months, 6 months
| Intervention | Score (Mean) | ||
|---|---|---|---|
| Baseline visit (0 weeks) | 6 Month visit (V2) | Change from Baseline | |
| Cohort 1a Sitters Placebo Then Treatment | 20.0 | 20.6 | 0.6 |
| Cohort 1b Sitters Treatment | 16.6 | 16.8 | 0.2 |
"Baseline Modified Hammersmith Extend testing. The baseline test is the score they receive during their screening visits. This scale ranges from 0 to 56. A higher score indicates a better outcome.~This scale is used to assess gross motor abilities of children with SMA in multiple research trials as well as in clinical settings." (NCT00227266)
Timeframe: 1 month prior to enrollment, at enrollment (0 months)
| Intervention | Score (Mean) | |
|---|---|---|
| Modified Hammersmith Extend at S1 (-4 weeks) | Modified Hammersmith Extend at S2 (0 weeks) | |
| Cohort 2 Experimental | 47.0 | 48.3 |
17 reviews available for carnitine and Diabetes Mellitus
| Article | Year |
|---|---|
Risks and benefits of carnitine supplementation in diabetes.
Topics: Carnitine; Diabetes Mellitus; Dietary Supplements; Humans; Risk | 2015 |
Fatty Acid Oxidation and Its Relation with Insulin Resistance and Associated Disorders.
Topics: Animals; Carnitine; Carnitine Acyltransferases; Deficiency Diseases; Diabetes Mellitus; Diet, High-F | 2016 |
Metabolomics for clinical use and research in chronic kidney disease.
Topics: Arginine; Biomarkers; Biomedical Research; Carnitine; Diabetes Mellitus; Humans; Lipid Metabolism; M | 2017 |
[Toward a more rational field-genetic epidemiology].
Topics: Animals; Carnitine; Case-Control Studies; Chromosome Mapping; Cloning, Molecular; Diabetes Mellitus; | 2010 |
Antioxidants in the treatment of diabetes.
Topics: Antioxidants; Ascorbic Acid; Carnitine; Clinical Trials as Topic; Diabetes Complications; Diabetes M | 2011 |
Carnitine derivatives: clinical usefulness.
Topics: Acetylcarnitine; Cardiotonic Agents; Cardiovascular Diseases; Carnitine; Cognition Disorders; Depres | 2012 |
[Inherited and acquired disorders of mitochondrial DNA].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Cardiomyopathies; Carnitine; Child; Dia | 2002 |
Carnitine metabolism and deficit--when supplementation is necessary?
Topics: Animals; Carnitine; Diabetes Mellitus; Energy Metabolism; Heart Failure; Humans; Mitochondria, Muscl | 2003 |
Carnitine metabolism and deficit--when supplementation is necessary?
Topics: Animals; Carnitine; Diabetes Mellitus; Energy Metabolism; Heart Failure; Humans; Mitochondria, Muscl | 2003 |
Carnitine metabolism and deficit--when supplementation is necessary?
Topics: Animals; Carnitine; Diabetes Mellitus; Energy Metabolism; Heart Failure; Humans; Mitochondria, Muscl | 2003 |
Carnitine metabolism and deficit--when supplementation is necessary?
Topics: Animals; Carnitine; Diabetes Mellitus; Energy Metabolism; Heart Failure; Humans; Mitochondria, Muscl | 2003 |
Carnitine metabolism and deficit--when supplementation is necessary?
Topics: Animals; Carnitine; Diabetes Mellitus; Energy Metabolism; Heart Failure; Humans; Mitochondria, Muscl | 2003 |
Carnitine metabolism and deficit--when supplementation is necessary?
Topics: Animals; Carnitine; Diabetes Mellitus; Energy Metabolism; Heart Failure; Humans; Mitochondria, Muscl | 2003 |
Carnitine metabolism and deficit--when supplementation is necessary?
Topics: Animals; Carnitine; Diabetes Mellitus; Energy Metabolism; Heart Failure; Humans; Mitochondria, Muscl | 2003 |
Carnitine metabolism and deficit--when supplementation is necessary?
Topics: Animals; Carnitine; Diabetes Mellitus; Energy Metabolism; Heart Failure; Humans; Mitochondria, Muscl | 2003 |
Carnitine metabolism and deficit--when supplementation is necessary?
Topics: Animals; Carnitine; Diabetes Mellitus; Energy Metabolism; Heart Failure; Humans; Mitochondria, Muscl | 2003 |
Role of antioxidants, essential fatty acids, carnitine, vitamins, phytochemicals and trace elements in the treatment of diabetes mellitus and its chronic complications.
Topics: Animals; Antioxidants; Carnitine; Diabetes Complications; Diabetes Mellitus; Fatty Acids, Essential; | 2006 |
[Metabolism of long chain fatty acids in the normal and pathologic heart: effects of ischemia].
Topics: Acyl Coenzyme A; Animals; Carnitine; Coenzyme A; Coronary Disease; Diabetes Mellitus; Dogs; Fatty Ac | 1984 |
The aetiology of diabetic neuropathy: the combined roles of metabolic and vascular defects.
Topics: Aldehyde Reductase; Animals; Carnitine; Cells; Diabetes Mellitus; Diabetes Mellitus, Experimental; D | 1995 |
The 1993 Merck Frosst Award. Acetyl-CoA carboxylase: an important regulator of fatty acid oxidation in the heart.
Topics: Acetyl Coenzyme A; Acetyl-CoA Carboxylase; Animals; Carbohydrate Metabolism; Carnitine; Carnitine O- | 1994 |
Metabolic cardiomyopathies.
Topics: Adult; Animals; Calcium; Cardiomegaly; Cardiomyopathies; Cardiomyopathy, Alcoholic; Carnitine; Diabe | 2000 |
Carnitine metabolism in human subjects. III. Metabolism in disease.
Topics: Adolescent; Adult; Animals; Carnitine; Carnitine Acyltransferases; Child; Diabetes Mellitus; Diabeti | 1978 |
Paradoxical role of lipid metabolism in heart function and dysfunction.
Topics: Adenosine Triphosphatases; Animals; Carnitine; Diabetes Complications; Diabetes Mellitus; Diabetes M | 1992 |
Diabetes-induced abnormalities in the myocardium.
Topics: Adenosine Triphosphatases; Animals; Blood Glucose; Calcium; Carbohydrate Metabolism; Cardiomyopathie | 1986 |
Heart triglycerides in health and disease.
Topics: Animals; Carnitine; Coenzyme A; Coronary Disease; Diabetes Mellitus; Fatty Acids, Nonesterified; Gly | 1973 |
1 trial available for carnitine and Diabetes Mellitus
| Article | Year |
|---|---|
Ketosis resistance in fibrocalculous pancreatic diabetes: II. Hepatic ketogenesis after oral medium-chain triglycerides.
Topics: Adipose Tissue; Administration, Oral; Adult; Blood Glucose; C-Peptide; Carnitine; Diabetes Complicat | 1997 |
52 other studies available for carnitine and Diabetes Mellitus
| Article | Year |
|---|---|
L-Carnitine Supplementation in the Diabetic Heart.
Topics: Carnitine; Diabetes Mellitus; Dietary Supplements; Heart; Humans; Myocardium | 2021 |
Effects of L-Carnitine Treatment on Kidney Mitochondria and Macrophages in Mice with Diabetic Nephropathy.
Topics: Animals; Carnitine; Diabetes Mellitus; Diabetic Nephropathies; DNA, Mitochondrial; Kidney; Macrophag | 2022 |
Targeted metabolomics analysis of amino acids and acylcarnitines as risk markers for diabetes by LC-MS/MS technique.
Topics: Amino Acids; Carnitine; Chromatography, Liquid; Diabetes Mellitus; Female; Humans; Male; Metabolomic | 2022 |
Circulating amino acids and acylcarnitines correlated with different CAC score ranges in diabetic postmenopausal women using LC-MS/MS based metabolomics approach.
Topics: Amino Acids; Cardiovascular Diseases; Carnitine; Chromatography, Liquid; Cross-Sectional Studies; Di | 2022 |
Chiral Luminescent Sensor Eu-BTB@d-Carnitine Applied in the Highly Effective Ratiometric Sensing of Curing Drugs and Biomarkers for Diabetes and Hypertension.
Topics: Biomarkers; Carnitine; Clonidine; Diabetes Mellitus; Europium; Humans; Hypertension; Insulins; Metal | 2022 |
L-carnitine alleviates cardiac microvascular dysfunction in diabetic cardiomyopathy by enhancing PINK1-Parkin-dependent mitophagy through the CPT1a-PHB2-PARL pathways.
Topics: Animals; Carnitine; Diabetes Mellitus; Diabetic Cardiomyopathies; Endothelial Cells; Male; Mice; Mit | 2023 |
Short and medium chain acylcarnitines as markers of outcome in diabetic and non-diabetic subjects with acute coronary syndromes.
Topics: Acetylcarnitine; Acute Coronary Syndrome; Carnitine; Clinical Studies as Topic; Cohort Studies; Diab | 2023 |
Plasma Metabolomic Markers of Insulin Resistance and Diabetes and Rate of Incident Parkinson's Disease.
Topics: Adult; Aged; Biomarkers; Carnitine; Diabetes Mellitus; Female; Humans; Insulin Resistance; Male; Met | 2020 |
Endotypes of primary osteoarthritis identified by plasma metabolomics analysis.
Topics: Aged; Arginine; Body Mass Index; Carnitine; Case-Control Studies; Coronary Disease; Diabetes Mellitu | 2021 |
Circulating metabolites and lipids are associated with glycaemic measures in South Asians.
Topics: Adult; Aged; Aged, 80 and over; Asia, Western; Betaine; Blood Glucose; Carnitine; Chromatography, Li | 2021 |
Exacerbation of cardiovascular ageing by diabetes mellitus and its associations with acyl-carnitines.
Topics: Aged; Aging; Cardiovascular System; Carnitine; Diabetes Mellitus; Female; Humans; Male; Middle Aged | 2021 |
Blood Metabolic Signatures of Body Mass Index: A Targeted Metabolomics Study in the EPIC Cohort.
Topics: Adult; Amino Acids; Bile Duct Neoplasms; Biogenic Amines; Blood Proteins; Body Mass Index; Carcinoma | 2017 |
Dietary stearic acid regulates mitochondria in vivo in humans.
Topics: Adult; Beverages; Carnitine; Case-Control Studies; Cross-Over Studies; Diabetes Mellitus; Diet; Fatt | 2018 |
Single nucleotide polymorphism in CPT1B and CPT2 genes and its association with blood carnitine levels in acute myocardial infarction patients.
Topics: Adult; Aged; Aged, 80 and over; Carnitine; Carnitine O-Palmitoyltransferase; Case-Control Studies; D | 2013 |
Obesity and lipid stress inhibit carnitine acetyltransferase activity.
Topics: Acetyl Coenzyme A; Animals; Carnitine; Carnitine O-Acetyltransferase; Carnitine O-Palmitoyltransfera | 2014 |
Decreased acylcarnitine content improves insulin sensitivity in experimental mice models of insulin resistance.
Topics: Animals; Blood Glucose; Carnitine; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diet, High-Fa | 2016 |
Diabetes is Associated with Higher Trimethylamine N-oxide Plasma Levels.
Topics: Age Factors; Aged; Animals; Body Mass Index; Cardiovascular Diseases; Carnitine; Diabetes Mellitus; | 2016 |
Superior Glucose Tolerance and Metabolomic Profiles, Independent of Adiposity, in HIV-Infected Women Compared With Men on Antiretroviral Therapy.
Topics: Absorptiometry, Photon; Adipose Tissue; Adiposity; Adult; Amino Acids, Branched-Chain; Anti-Retrovir | 2016 |
Toward personalized hemodialysis by low molecular weight amino-containing compounds: future perspective of patient metabolic fingerprint.
Topics: Aged; Amino Acids; Carnitine; Diabetes Mellitus; Female; Forecasting; Humans; Male; Metabolomics; Pr | 2012 |
The pattern of urinary acylcarnitines determined by electrospray mass spectrometry: a new tool in the diagnosis of diabetes mellitus.
Topics: Adult; Aged; Body Mass Index; Calibration; Carnitine; Diabetes Mellitus; Humans; Middle Aged; Spectr | 2003 |
[Effects of carnitine carnitate on the humoral balance of diabetics].
Topics: Carnitine; Diabetes Mellitus; Humans; Lipids; Vitamin B Complex | 1957 |
[Effect of carnitine on diabetic hyperlipemia].
Topics: Carnitine; Diabetes Complications; Diabetes Mellitus; Folic Acid; Humans; Hyperlipidemias; Lipids; V | 1960 |
Serum carnitine concentrations correlated to clinical outcome parameters in chronic hemodialysis patients.
Topics: Age Factors; Blood Urea Nitrogen; Carnitine; Diabetes Complications; Diabetes Mellitus; Female; Huma | 2004 |
Effects of very low-fat diets on anginal symptoms.
Topics: Acetanilides; Angina Pectoris; Carnitine; Chemotherapy, Adjuvant; Diabetes Complications; Diabetes M | 2004 |
The crystal structure of carnitine palmitoyltransferase 2 and implications for diabetes treatment.
Topics: Amino Acid Sequence; Animals; Betaine; Binding Sites; Carnitine; Carnitine O-Palmitoyltransferase; C | 2006 |
L-Carnitine inhibits protein glycation in vitro and in vivo: evidence for a role in diabetic management.
Topics: Animals; Blood Glucose; Carnitine; Diabetes Mellitus; Diaphragm; Dietary Carbohydrates; Fructosamine | 2007 |
Association of carnitine deficiency in Indian continuous ambulatory peritoneal dialysis patients with anemia, erythropoietin use, residual renal function, and diabetes mellitus.
Topics: Adult; Aged; Anemia; Carnitine; Chi-Square Distribution; Diabetes Mellitus; Erythropoietin; Female; | 2007 |
Metabolic agents in the management of diabetic coronary patients: a new era.
Topics: Carnitine; Coronary Disease; Diabetes Mellitus; Diabetic Angiopathies; Dichloroacetic Acid; Enzyme I | 2008 |
Bioinformatics analysis of targeted metabolomics--uncovering old and new tales of diabetic mice under medication.
Topics: Amino Acids; Animals; Carnitine; Computational Biology; Diabetes Mellitus; Gluconeogenesis; Hypoglyc | 2008 |
Acute hormonal effects on carnitine metabolism in thin and obese subjects: responses to somatostatin, glucagon, and insulin.
Topics: Adult; Blood Glucose; Carnitine; Diabetes Mellitus; Fatty Acids, Nonesterified; Female; Glucagon; Hu | 1981 |
Maturity-onset diabetes mellitus--toward a physiological appropriate management.
Topics: Amino Acids; Aspirin; Carnitine; Chromium; Diabetes Mellitus; Dietary Fats; Dietary Fiber; Fasting; | 1981 |
Rationales for micronutrient supplementation in diabetes.
Topics: Animals; Antioxidants; Ascorbic Acid; Calcium; Carnitine; Chromium; Diabetes Mellitus; gamma-Linolen | 1984 |
["Metabolic" myocardiopathies in childhood (author's transl)].
Topics: Cardiomyopathies; Carnitine; Diabetes Mellitus; Echocardiography; Glycogen Storage Disease; Humans; | 1981 |
Plasma and urine free L-carnitine in human diabetes mellitus.
Topics: Blood Glucose; Carnitine; Cholesterol; Diabetes Mellitus; Fatty Acids, Nonesterified; Female; Humans | 1981 |
Carnitine content of liver from genetically diabetic (db/db) and control mice.
Topics: Aging; Animals; Carnitine; Diabetes Mellitus; Fatty Acids, Nonesterified; Liver; Mice; Mice, Inbred | 1981 |
Serum and urine levels of levocarnitine family components in genetically diabetic rats.
Topics: Acetylcarnitine; Animals; Blood Glucose; Body Weight; Carnitine; Diabetes Mellitus; Diuresis; Female | 1994 |
Changes in carnitine metabolism with ketone body production in obese glucose-intolerant patients.
Topics: Acylation; Adult; Blood Glucose; Carnitine; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose In | 1995 |
Utility of metformin as an adjunct to hydroxycitrate/carnitine for reducing body fat in diabetics.
Topics: Adipose Tissue; Body Composition; Carnitine; Citrates; Diabetes Mellitus; Humans; Hypoglycemic Agent | 1998 |
Low levels of serum acylcarnitine in chronic fatigue syndrome and chronic hepatitis type C, but not seen in other diseases.
Topics: Acute Disease; Animals; Carnitine; Chemical and Drug Induced Liver Injury; Diabetes Mellitus; Fatigu | 1998 |
Effect of D,L-carnitine, acetyl-D,L-beta-methylcholine chloride and glycine betaine on some processes of carbohydrate metabolism of humans and goats.
Topics: Adult; Aged; Alanine Transaminase; Animals; Aspartate Aminotransferases; Betaine; Blood Glucose; Car | 1979 |
The heart in diabetes mellitus.
Topics: Animals; Carnitine; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, | 1979 |
The decreases with age in the activities of enzymes of human skeletal muscle. Some observations on palmityl-carnitine formation, hexokinase activity, and lactate dehydrogenase activity.
Topics: Adolescent; Adult; Aging; Carnitine; Diabetes Mellitus; Female; Hexokinase; Humans; L-Lactate Dehydr | 1978 |
Carnitine concentration in skeletal muscle tissue from patients with diabetes mellitus.
Topics: Acetyl Coenzyme A; Aged; Carnitine; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Insulin; | 1977 |
Serum and tissue carnitine assay based on dialysis.
Topics: Carnitine; Carnitine O-Acetyltransferase; Diabetes Mellitus; Dialysis; Dithionitrobenzoic Acid; Huma | 1992 |
Differential excretion of xenobiotic acyl-esters of carnitine due to administration of pivampicillin and valproate.
Topics: Adolescent; Adult; Ampicillin; Carnitine; Child; Cholesterol; Chromatography, Gas; Diabetes Mellitus | 1990 |
[Determination of serum L-carnitine by an implication of Cobas Bio centrifugal analyzer and its clinical implication in health and disease].
Topics: Adult; Aged; Carnitine; Centrifugation; Colorimetry; Diabetes Mellitus; Female; Humans; Kidney Failu | 1988 |
The effect of streptozotocin-induced diabetes on oxidative phosphorylation and related reactions in skeletal muscle mitochondria.
Topics: Adenosine Diphosphate; Adenosine Triphosphatases; Adenosine Triphosphate; Animals; Antineoplastic Ag | 1972 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
Carnitine levels in human serum in health and disease.
Topics: Acetyl Coenzyme A; Acetyltransferases; Anorexia Nervosa; Benzoates; Carbon Radioisotopes; Cardiomega | 1974 |
-Oxoglutarate carboxylation in liver mitochondria from normal, alloxan diabetic and streptozotocin diabetic rats.
Topics: Animals; Caprylates; Carbon Dioxide; Carnitine; Citrates; Citric Acid Cycle; Cyclic AMP; Depression, | 1972 |
In vitro studies on the metabolism of hexadecanedioic acid and its mono-L-carnitine ester.
Topics: Acyltransferases; Animals; Carnitine; Clofibrate; Coenzyme A; Diabetes Mellitus; Esters; Fasting; Ma | 1973 |
Pathogenesis of ketonemia.
Topics: Acetoacetates; Acidosis; Animals; Carnitine; Coenzyme A; Diabetes Mellitus; Fasting; Gluconeogenesis | 1969 |
Citrate and the conversion of carbohydrate into fat.
Topics: Acetates; Acyltransferases; Animals; Carbohydrate Metabolism; Carnitine; Citrates; Coenzyme A; Diabe | 1968 |